Treating VVA: Objective and Subjective Measure of Benefit

Article

Approved treatments of menopause-related symptoms can have narrow indications, but they may offer broader relief of the most bothersome menopause symptoms.

Drug therapies for symptoms related to genituourinary syndrome of menopause (GSM) tend to have narrow indications of use. Ospemifene, for example, has been approved for the treatment of dyspareunia, or painful sex, in postmenopausal women. But new research shows that it may have additional benefits as well.

In this video, David Portman, MD, of the Columbus Center for Women's Health Research, Columbus, Ohio, discusses the research, which shows that ospemifene is associated not only with improvements in symptoms of dyspareunia but also with improvements of a woman's "most bothersome" symptom of menopause, whatever she defines that to be.

This research was presented in October 2014 at the 25th Annual Meeting of The North American Menopause Society.

Recent Videos
How fezolinetant advances non-hormonal treatment of hot flashes | Image Credit: medschool.cuanschutz.edu
Rossella Nappi, MD, discusses benefits of fezolinetant against vasomotor symptoms | Image Credit: imsociety.org
JoAnn Pinkerton discusses elinzanetant's crucial role in VMS therapy | Image Credit: uvahealth.com
Empowering women to take charge of their health | Image Credit: © piecesofi.com - © piecesofi.com - stock.adobe.com.
Supporting women through menopause with knowledge and care | Image Credit: © SHOTPRIME STUDIO - © SHOTPRIME STUDIO - stock.adobe.com.
How fezolinetant revolutionizes non-hormonal menopause therapy | Image Credit: imsociety.org
Gulf War exposures linked to early menopause in women veterans | Image Credit: linkedin.com.
Vanessa Muñiz discusses benefits of clinical hypnosis against hot flashes | Image Credit: mindbodymedicine.artsandsciences.baylor.edu
Related Content
© 2024 MJH Life Sciences

All rights reserved.